Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Humacyte Inc (HUMA)

Humacyte Inc (HUMA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 583,986
  • Shares Outstanding, K 125,859
  • Annual Sales, $ 0 K
  • Annual Income, $ -110,780 K
  • EBIT $ -112 M
  • EBITDA $ -104 M
  • 60-Month Beta 1.38
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 203.16% ( +29.03%)
  • Historical Volatility 121.62%
  • IV Percentile 98%
  • IV Rank 66.30%
  • IV High 273.17% on 12/09/24
  • IV Low 65.46% on 12/28/23
  • Put/Call Vol Ratio 0.55
  • Today's Volume 58,869
  • Volume Avg (30-Day) 9,024
  • Put/Call OI Ratio 0.46
  • Today's Open Interest 132,545
  • Open Int (30-Day) 105,910

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.24
  • Number of Estimates 2
  • High Estimate -0.22
  • Low Estimate -0.26
  • Prior Year -0.24
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.37 +37.69%
on 12/19/24
6.77 -31.46%
on 12/20/24
+0.23 (+5.22%)
since 11/20/24
3-Month
3.37 +37.69%
on 12/19/24
6.77 -31.46%
on 12/20/24
-0.56 (-10.77%)
since 09/20/24
52-Week
2.48 +87.10%
on 01/17/24
9.97 -53.46%
on 05/31/24
+1.90 (+69.34%)
since 12/20/23

Most Recent Stories

More News
Humacyte Stock Hits Over 1-Month Highs On FDA Nod For Bioengineered Tissue In Treating Vascular Trauma, Retail Interest Soars

Real-world evidence from its humanitarian use in Ukraine to treat wartime injuries further bolstered the company’s biologics license application.

HUMA : 4.64 (+34.10%)
Humacyte, Inc. Announces FDA Approval for SYMVESS as First-in-Class Bioengineered Vascular Conduit for Arterial Injury Repair

Humacyte's SYMVESS receives FDA approval as a bioengineered vascular conduit with promising clinical outcomes for arterial injury repair.Quiver AI SummaryHumacyte, Inc. has announced that the FDA has granted...

HUMA : 4.64 (+34.10%)
Humacyte Announces FDA Approval of SYMVESSâ„¢ (acellular tissue engineered vessel-tyod) for the Treatment of Extremity Vascular Trauma

HUMA : 4.64 (+34.10%)
FDA delays and weak fundamentals cloud Humacyte’s (HUMA) future prospects

Humacyte (HUMA) faces mounting investor scrutiny as a class action lawsuit alleges the company failed to disclose critical manufacturing deficiencies at its Durham, North Carolina facility. These issues,...

HUMA : 4.64 (+34.10%)
Regulatory delays pressure Humacyte’s (HUMA) cash reserves

Humacyte's (HUMA) innovative Acellular Tissue Engineered Vessel (ATEV) technology remains promising, but the FDA’s delay in approving its lead product for vascular trauma has placed the company in a...

HUMA : 4.64 (+34.10%)
Manufacturing lapses lead to legal action against Humacyte (HUMA)

Humacyte (HUMA) faces mounting legal challenges as a class action lawsuit has been filed against the company for alleged violations of federal securities laws. The lawsuit, filed on behalf of investors...

HUMA : 4.64 (+34.10%)
Humacyte, Inc. CEO Laura Niklason to Speak at Piper Sandler 36th Annual Healthcare Conference on December 5, 2024

Humacyte, Inc. CEO Laura Niklason will present at the Piper Sandler Healthcare Conference on December 5, 2024, in New York.Quiver AI SummaryHumacyte, Inc. has announced that its Founder, President, and...

HUMA : 4.64 (+34.10%)
Humacyte to Present at the Piper Sandler 36th Annual Healthcare Conference

HUMA : 4.64 (+34.10%)
Humacyte (HUMA) Insiders Show Confidence Despite Stock Decline

Insider activity at Humacyte (HUMA) has drawn attention after a 17% drop in the company’s stock price over the past year. Insiders, including founder Laura Niklason and board member Gordon Binder, collectively...

HUMA : 4.64 (+34.10%)
Humacyte to Present Efficacy and Safety Results from V007 Phase 3 AV Access Clinical Trial at the 51st Annual Symposium on Vascular and Endovascular Issues, Techniques and Horizons (VEITH)

HUMA : 4.64 (+34.10%)

Business Summary

Humacyte Inc. is a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale. Humacyte Inc., formerly known as Alpha Healthcare Acquisition Corp., is based in DURHAM, N.C.

See More

Key Turning Points

3rd Resistance Point 8.44
2nd Resistance Point 7.61
1st Resistance Point 6.12
Last Price 4.64
1st Support Level 3.80
2nd Support Level 2.97
3rd Support Level 1.48

See More

52-Week High 9.97
Fibonacci 61.8% 7.11
Fibonacci 50% 6.23
Fibonacci 38.2% 5.34
Last Price 4.64
52-Week Low 2.48

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar